ENCLAI Daily · Article of the day 07 Oct 2026 · ENCLAI Editorial

ACP guideline recommends estrogen as first-line treatment for menopausal hot flashes

GuidelineAnnals of internal medicine · 6 Oct 2026 · PubMed 42832802
Statement

When selecting a treatment of vasomotor symptoms, clinicians should use an informed decision-making approach and discuss benefits, harms, contraindications, comorbid conditions, values and preferences, financial burden, and access to and availability of treatments.

Strength of recommendation“METHODS: The ACP Clinical Guidelines Committee developed this guideline based on systematic reviews on effectiveness, comparative effectiveness, harms, public and patient values and preferences, and economic evidence of pharmacologic treatments for females with menopausal vasomotor symptoms using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.”
Statements are quoted word for word from the published abstract; the labels come from each statement’s own wording (“is recommended”, “should”, “may be preferred”, “should not”). Read the full guidance before applying it.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

The American College of Physicians recommends estrogen as the first-line pharmacologic treatment for females with menopausal vasomotor symptoms. For women with a uterus, the guideline advises estrogen combined with progestogen, while estrogen monotherapy is recommended for those without a uterus.

Who the findings apply to

The guideline applies to females seeking treatment for menopausal vasomotor symptoms in outpatient settings.

First-line recommendations target females with or without a uterus who do not have contraindications to hormone therapy.

Second-line and third-line recommendations apply to females who have contraindications to or do not tolerate first-line or second-line treatments.

Why this matters

This guideline provides a structured, evidence-based hierarchy for clinicians managing menopausal symptoms in outpatient settings. By distinguishing between first-line, second-line, and third-line options based on certainty of evidence and patient tolerance, it supports informed decision-making regarding benefits, harms, and patient preferences.

What the study found

ACP recommends initiating estrogen in combination with progestogen in females with a uterus, based on high-certainty evidence.

ACP recommends initiating estrogen monotherapy in females without a uterus, based on high-certainty evidence.

For those who cannot use first-line treatment, ACP suggests serotonin-norepinephrine reuptake inhibitors, specifically desvenlafaxine or venlafaxine, based on moderate-certainty evidence.

For those who cannot use first- or second-line treatment, ACP suggests selective serotonin reuptake inhibitors (escitalopram or paroxetine), gabapentin, or neurokinin receptor antagonists (elinzanetant or fezolinetant).

What the result does not establish

The guideline is based on systematic reviews using the GRADE approach, with varying levels of certainty for different treatment tiers.

Second-line recommendations for serotonin-norepinephrine reuptake inhibitors are conditional, supported by moderate-certainty evidence.

Third-line recommendations for selective serotonin reuptake inhibitors and gabapentin are conditional, supported by low-certainty evidence.

Third-line recommendations for neurokinin receptor antagonists are conditional, supported by moderate-certainty evidence.

Clinicians must use an informed decision-making approach, discussing benefits, harms, contraindications, comorbid conditions, values, preferences, financial burden, and access to treatments.

Authors’ conclusion

“ACP suggests that clinicians use one of the following in females who have contraindications to or do not tolerate first-line or second-line treatment (conditional recommendation): selective serotonin reuptake inhibitors, either escitalopram or paroxetine (low-certainty evidence); the gabapentinoid gabapentin (low-certainty evidence); or neurokinin receptor antagonists, either elinzanetant or fezolinetant…”

Study and sources

Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians

Guidelines & recommendations · Annals of internal medicine · 2026-10-06

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.